Literature DB >> 16394055

Incorporating first-trimester Down syndrome studies into prenatal screening: executive summary of the National Institute of Child Health and Human Development workshop.

Uma M Reddy1, Michael T Mennuti.   

Abstract

The National Institute of Child Health and Human Development (NICHD), the Society for Maternal-Fetal Medicine, and the American College of Obstetricians and Gynecologists (ACOG), cosponsored a workshop on December 16-17, 2004, to discuss the evidence for first-trimester Down syndrome screening and to explore the effects of combining first- and second-trimester screening, given the results of recent U.S. trials. The experts evaluated the evidence for offering first-trimester screening to provide individual risk assessment for Down syndrome. First-trimester screening has been demonstrated to provide efficient Down syndrome risk assessment, with a detection rate of 84% (95% confidence interval 80-87%), which is clinically comparable to the second-trimester quadruple screen at a fixed false-positive rate of 5%. The participants at the workshop concluded that at this time there is sufficient evidence to support implementing first-trimester Down syndrome risk assessment in obstetric practice in the United States, provided that certain requirements can be met. These requirements include training and quality control standards for first-trimester nuchal translucency measurement and laboratory assays, access to chorionic villus sampling, and appropriate counseling regarding screening options.

Entities:  

Mesh:

Year:  2006        PMID: 16394055     DOI: 10.1097/01.AOG.0000194186.34664.a9

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  4 in total

1.  Trisomy 21 in one of extremely low birth weight twins.

Authors:  Benjamin D Solomon; Divya Balachandar; Karen Perry; Nuria Carrillo-Carrasco; Thomas C Markello; Khodayar Rais-Bahrami
Journal:  J Neonatal Perinatal Med       Date:  2008-01-01

2.  2D DIGE analysis of maternal plasma for potential biomarkers of Down Syndrome.

Authors:  Wendy E Heywood; Tracey E Madgett; Darrell Wang; Amanda Wallington; Julie Hogg; Kevin Mills; Neil D Avent
Journal:  Proteome Sci       Date:  2011-09-19       Impact factor: 2.480

3.  Non-invasive epigenetic detection of fetal trisomy 21 in first trimester maternal plasma.

Authors:  Ji Hyae Lim; Shin Young Kim; So Yeon Park; Shin Yeong Lee; Mi Jin Kim; You Jung Han; Si Won Lee; Jin Hoon Chung; Moon Young Kim; Jae Hyug Yang; Hyun Mee Ryu
Journal:  PLoS One       Date:  2011-11-23       Impact factor: 3.240

4.  Impact of a new national screening policy for Down's syndrome in Denmark: population based cohort study.

Authors:  Charlotte K Ekelund; Finn Stener Jørgensen; Olav Bjørn Petersen; Karin Sundberg; Ann Tabor
Journal:  BMJ       Date:  2008-11-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.